Weekly Special Report: Moderna (#MODERNA)

 

THE COMPANY:

• MODERNA'S BUSINESS: Moderna develops mRNA-based medicines and vaccines. Its technology uses messenger RNA to instruct cells to produce proteins that can help the body prevent or fight diseases. Moderna's products and pipeline cover respiratory viruses, cancer, infectious diseases, and other medical conditions.
• MODERNA'S KEY PRODUCTS: Moderna's main commercial products include Spikevax, its COVID-19 vaccine, and mRESVIA, its respiratory syncytial virus (RSV) vaccine. The company is working to expand its vaccine business while developing new mRNA-based treatments.
• MODERNA'S CANCER VACCINE: Moderna is developing a personalized cancer vaccine using mRNA technology in partnership with Merck. The vaccine is designed to train the immune system to recognize and attack cancer cells. The most important program is being developed alongside Merck's Keytruda cancer treatment.
• MODERNA'S LATEST PIPELINE: Moderna has a large pipeline of mRNA-based vaccines and treatments. Major programs include personalized cancer vaccines, influenza vaccines, combination COVID-19/influenza vaccines, RSV vaccines, and vaccines targeting other infectious diseases.

 

MODERNA: EVENTS

• FRIDAY, OCTOBER 9: MODERNA TO RE-JOIN NASDAQ 100 (USA100) INDEX. Moderna is set to join the Nasdaq-100 index before the market opens on October 9, replacing Warner Bros. Discovery. The inclusion could increase demand for Moderna shares from passive funds tracking the index.
• SATURDAY, OCTOBER 24: MODERNA AND MERCK TO PRESENT PHASE 3 DATA FOR PERSONALIZED mRNA CANCER VACCINE. Moderna and Merck are scheduled to present detailed Phase 3 data for their personalized mRNA cancer vaccine intismeran autogene, in combination with Merck's Keytruda, at the ESMO Congress in Madrid.
• THURSDAY, OCTOBER 29, PREMARKET (EXPECTED): Q3 EARNINGS REPORT. The company is expected to print around 887 million in revenue, up around 511% from Q2 of 2026. The company is expected to print a net loss equal to $426 million, down from its net loss in Q2 of 782 million dollars.  

 

MODERNA: SKIN CANCER VACCINE MILESTONE ANNOUNCED

• BREAKING (AUGUST 19): MODERNA AND MERCK ANNOUNCED SUCCESSFUL LATE-STAGE TRIAL RESULTS WITH SKIN CANCER VACCINE. Moderna and Merck announced that their personalized mRNA cancer treatment, intismeran, succeeded in a large Phase 3 trial for melanoma, an aggressive form of skin cancer. The trial involved 1,137 patients whose melanoma had been surgically removed. The treatment was given together with Merck's existing cancer drug Keytruda. The results showed the cancer was less likely to come back, the cancer was less likely to spread to other parts of the body, and there were no new safety concerns reported.
• NEXT PHASE: REGULATORY REVIEW. Regulators at the U.S. Food and Drug Administration (FDA) will examine effectiveness and safety. The companies have not yet announced a specific FDA filing date.
• POSSIBLE APPROVAL: Potentially as early as next year (2027).
• POTENTIAL COMMERCIAL SALES BEGIN: Potentially 2027.

 

MODERNA: PRICE ACTION AND TECHNICAL ANALYSIS

• STRONG SUPPORT AREA: $170–$150. Moderna’s share price has found support in the $170–$150 area after rising by around 235% between August 19 and October 6, 2026.
• MODERNA STOCK PRICE HIT AN ALL-TIME HIGH OF $498.28 (August, 2021). Moderna stock price currently trades at $189, and if a full recovery to its previous all-time high occurs, it could see an upside potential of around 162%. However, it could also decline.

GRAPH (Weekly): August 2020 – October 2026

Please note that past performance does not guarantee future results

 

#MODERNA, October 6, 2026
Current Price:    189

 

Example of calculation based on weekly market trend for 1.00 Lot¹

1.  The above calculations are made based on 1.00 lot which is equivalent of 1000 units
2.  Calculations for exchange rate used as of 15:00 (GMT+1) 06/10/2026

 

You can use risk management tools such as Stop-Loss and Take-Profit